Study guide
19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
Key Takeaways Explain This Topic AI
The United States maternal mortality crisis demonstrates severe racial inequities: Black women are 3 to 4 times and Indigenous women 2 to 3 times more likely to die from pregnancy-related causes than White women, independent of income or education.
Maternal Mortality Review Committees (MMRCs) determine that >80% of pregnancy-related deaths are preventable; the leading underlying causes are mental health conditions (suicide and overdose), hemorrhage, and cardiovascular conditions.
The weathering hypothesis demonstrates how structural racism and cumulative allostatic load accelerate biological aging and vascular dysfunction, necessitating systemic interventions like AIM safety bundles and community doulas.
Cultural humility emphasizes lifelong self-critique, redressing clinical power imbalances, and viewing patients as experts in their lived experience, moving beyond the checklist approach of cultural competence.
Gender-affirming care requires organ-based preventive screening (cervical cytology for anyone with a cervix); exogenous testosterone induces amenorrhea but is NOT contraception and is teratogenic, requiring compatible progestin or copper contraception.
Last updated: October 2026
The United States Maternal Mortality Crisis & Racial Disparities
The United States maintains the highest maternal mortality rate among high-income nations. The Centers for Disease Control and Prevention (CDC) monitors maternal deaths using the Pregnancy-Related Mortality Ratio (PRMR) , defined as the number of pregnancy-related deaths per 100,000 live births occurring during pregnancy or within one year postpartum from any cause related to or aggravated by pregnancy or its management.
Severe Racial & Ethnic Inequities
U.S. maternal mortality is characterized by persistent, stark racial disparities:
Non-Hispanic Black Women: Experience a PRMR 3 to 4 times higher than non-Hispanic White women (approximately 40 to 55 vs. 13 to 17 deaths per 100,000 live births).
American Indian and Alaska Native (AI/AN) Women: Experience a PRMR 2 to 3 times higher than White women.
Independence from Socioeconomic Status: Epidemiological data show these racial disparities persist across all income levels and educational strata; a Black woman with a graduate degree faces higher maternal mortality risk than a White woman without a high school diploma, demonstrating that structural inequities rather than individual biology or socioeconomic status drive disparities.
Preventability & Leading Causes
State Maternal Mortality Review Committees (MMRCs) —multidisciplinary expert panels that investigate every maternal death—consistently report that greater than 80% of pregnancy-related deaths are preventable .
The leading underlying causes of pregnancy-related mortality include:
Mental Health Conditions: The leading underlying cause in CDC maternal mortality review data (about 23% of pregnancy-related deaths through 2021 and about 28% in 2022), driven by suicide and overdose and concentrated in the late postpartum period (43–365 days).
Obstetric Hemorrhage: Severe postpartum blood loss from uterine atony, placenta accreta spectrum, or genital tract trauma.
Infection / Sepsis: Puerperal endometritis, chorioamnionitis, and septic shock.
Cardiovascular Conditions & Cardiomyopathy: Cardiac and coronary conditions plus peripartum cardiomyopathy together rank among the top causes, especially for Black women.
Hypertensive Disorders of Pregnancy: Preeclampsia with severe features, eclampsia, and HELLP syndrome causing intracranial hemorrhage or end-organ failure.
Thrombotic Pulmonary Embolism: Deep venous thrombosis and pulmonary embolism fueled by pregnancy-induced hypercoagulability.
- Structural Determinants, Chronic Allostatic Load & The Weathering Hypothesis
- The Weathering Hypothesis
Developed by Dr. Arline Geronimus, the weathering hypothesis posits that Black women experience chronic, cumulative exposure to social adversity, systemic racism, and environmental injustice, inducing high allostatic load —chronic physiological dysregulation characterized by elevated cortisol, circulating catecholamines, and endothelial inflammation. Over decades, this chronic neuroendocrine activation accelerates biological aging and induces premature vascular dysfunction. Black women frequently enter pregnancy with underlying vascular wear and tear, significantly increasing their susceptibility to early-onset preeclampsia, chronic hypertension, and cardiovascular collapse.
Historical Medical Exploitation & Medical Mistrust
Medical mistrust in marginalized communities stems from documented systemic exploitation:
J. Marion Sims: Developed gynecologic surgical techniques (vesicovaginal fistula repair) through non-consensual experimental surgeries on enslaved Black women (Anarcha, Betsey, Lucy) without anesthesia.
Tuskegee Syphilis Study: Four-decade withholding of known curative penicillin therapy from Black men with syphilis by the U.S. Public Health Service.
Coerced & Involuntary Sterilizations: Widespread federally funded involuntary sterilizations of Indigenous, Black, Puerto Rican, and disabled women throughout the 20th century ( Relf v. Weinberger , 1973).
Clinicians must acknowledge this historical reality, address implicit bias, and actively build therapeutic trust.
Evidence-Based Interventions: AIM Safety Bundles & Community Doulas
Alliance for Innovation on Maternal Health (AIM) Safety Bundles: Standardized, multidisciplinary clinical safety toolkits organized around the 4 "Rs": Readiness, Recognition & Prevention, Response, and Reporting & Systems Learning . Key bundles include:
Severe Hypertension in Pregnancy: Mandates immediate administration of first-line intravenous antihypertensives (IV labetalol, IV hydralazine) or oral immediate-release nifedipine within 30 to 60 minutes of persistent severe-range blood pressure (systolic BP ≥160 mmHg and/or diastolic BP ≥110 mmHg).
Obstetric Hemorrhage: Employs cumulative quantitative blood loss (QBL) measurement rather than visual estimation, stage-based hemorrhage protocols, and rapid uterotonic administration.
Community Doula Integration: Culturally concordant doulas provide continuous labor support, patient advocacy, and postpartum accompaniment, significantly reducing cesarean delivery rates, improving maternal satisfaction, and mitigating racial disparities in clinical communication.
Cultural Humility versus Cultural Competence
Dimension Cultural Competence Cultural Humility
Underlying Philosophy Views culture as a static set of traits and beliefs to be mastered through checklists and educational modules. Views culture as dynamic, intersectional, and unique to the individual; rejects the notion of cultural "mastery."
Primary Goal Knowledge acquisition and behavioral competence regarding specific demographic groups. Lifelong commitment to rigorous self-evaluation, self-critique, and awareness of implicit biases.
Clinical Power Dynamics Retains traditional hierarchy where the clinician acts as the objective expert evaluating the patient. Actively redresses clinical power imbalances, establishing partnerships where the patient is the recognized expert in their own lived experience.
Institutional Focus Emphasizes individual provider interpersonal skills. Demands institutional accountability, systemic advocacy, and structural transformation to dismantle health inequities.
Note
Origins: Coined in 1998 by Melanie Tervalon and Jann Murray-García, cultural humility shifts medical practice from a fixed educational milestone to a continuous, lifelong process of self-critique and egalitarian partnership.
Gender-Affirming Gynecologic & Reproductive Care
Advanced practice nurses provide gynecologic care to transgender men, non-binary individuals, and gender-diverse patients with female-assigned reproductive organs.
Affirming Communication & Clinical Environment
Inclusive Terminology: Consistently use the patient's affirmed name, legal name when necessary, and pronouns (she/her, he/him, they/them). Adopt affirming, organ-specific terms based on patient preference (e.g., "internal exam" or "front pelvic examination" instead of "vaginal exam"; "chestfeeding" or "bodyfeeding"; "gonads" or "ovaries").
Dysphoria Reduction: Use the smallest appropriate speculum (Pedersen or pediatric), offer topical 4% lidocaine gel, allow patient-assisted speculum insertion, and offer a support chaperone.
Organ-Based Screening & Atrophy Management
Cervical Cancer Screening: Guidelines (USPSTF/ASCCP) apply based on organ inventory , regardless of gender identity. Anyone with a cervix aged 21 to 65 requires routine cytology and hrHPV screening.
Managing Testosterone-Induced Atrophy: Exogenous testosterone induces severe vaginal and cervical squamous atrophy, leading to dyspareunia, exam pain, and high rates of unsatisfactory cytology or false-positive ASC-US results.
Topical Estrogen Pre-Treatment: Prescribe a 1- to 2-week course of topical vaginal estrogen (e.g., 0.01% estradiol cream or 10 mcg vaginal tablets nightly for 10–14 days) prior to repeat Pap screening. Topical estrogen restores squamous maturation and diagnostic cellularity without compromising systemic virilization or altering circulating testosterone levels.
Gender-Affirming Hormone Therapy (GAHT) & Contraceptive Counseling
Testosterone & Amenorrhea: Exogenous testosterone induces virilization and leads to amenorrhea in 85% to 90% of patients within 3 to 6 months.
CRITICAL FACT: Testosterone is NOT Contraception: Ovulation can occur unpredictably despite complete amenorrhea. Transgender men having intercourse with sperm-producing partners can conceive while on testosterone.
Teratogenicity: Testosterone is a potent teratogen that causes virilization of a female fetus and reproductive tract anomalies.
Compatible Contraception:
Intrauterine Devices: The 52 mg levonorgestrel IUD (LNG-IUD) is an ideal first-line method; it provides >99% contraceptive efficacy, reduces residual spotting, and does not alter systemic testosterone. Copper IUDs and subdermal etonogestrel implants are also fully compatible.
Progestin-Only Methods: DMPA and progestin-only pills (POPs) are fully compatible and do not cause feminization.
Estrogen-Containing Methods: Generally avoided due to patient dysphoria related to potential breast tenderness or perceived feminization.
Preconception & Fertility Preservation: Clinicians must counsel patients regarding fertility preservation options (oocyte cryopreservation, embryo banking) prior to initiating GAHT or undergoing gender-affirming gonadectomy. Testosterone must be stopped prior to conception due to teratogenic risks.